Skip to main content

Advertisement

SpringerLink
Log in

Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Over recent years, several reports have been published on unusual cases of osteonecrosis of the jaw (ONJ) in adults using second- and third-generation nitrogen-containing bisphosphonates such as pamidronate, alendronate, risedronate and zoledronate, but no case has ever been reported either in children or in adult patients taking neridronate. Children and adolescents affected by osteogenesis imperfecta (OI) could belong to a high-risk group for ONJ because bone fragility in OI is associated with a connective tissue malfunction. The purpose of this study is to evaluate the incidence of ONJ in a pediatric population treated with neridronate for OI. A total of 102 pediatric patients with OI who received neridronate infusions for a mean of 6.81 years (SD ± 3.06 years) were clinically assessed for possible ONJ. Eligibility criteria for participation included patients between 1.2 and 24 years old who received cyclical neridronate infusions for at least 1 year. All the patients were reviewed to determine duration, dosage and cumulative dose of their bisphosphonate therapy and were examined clinically to assess their oral health status. We have not demonstrated any occurrence of ONJ in our patients. In conclusion, at the moment insufficient data are available to prove a greater risk of ONJ in children with OI than in children affected by other forms of bone fragility. However, cases may emerge in future because the risk of ONJ seems to be related to the cumulative dose and the duration of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ONJ:

Osteonecrosis of the jaw

OI:

Osteogenesis imperfecta

References

  1. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet Part A 155:943–968

    Article  CAS  Google Scholar 

  2. Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F (2010) Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 6:367–381

    PubMed  Google Scholar 

  3. Glorieux FH (2001) Osteogenesis imperfecta. A disease of the osteoblast. Lancet 358:S45

  4. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Min Res 20:758–763

    Article  CAS  Google Scholar 

  5. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Article  PubMed  CAS  Google Scholar 

  6. Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L (2006) Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149:174–179

    Article  PubMed  CAS  Google Scholar 

  7. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G (1997) Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622–625

    Article  PubMed  CAS  Google Scholar 

  8. Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614

    Article  PubMed  CAS  Google Scholar 

  9. Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847

    Article  PubMed  CAS  Google Scholar 

  10. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575

    Article  PubMed  Google Scholar 

  11. Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136:1675–1681

    PubMed  CAS  Google Scholar 

  12. Levin L, Laviv A, Schwartz-Arad D (2007) Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 138:1218–1220

    PubMed  Google Scholar 

  13. Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021

    Article  PubMed  CAS  Google Scholar 

  14. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF (2009) Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140:61–66

    PubMed  Google Scholar 

  15. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol 18:3262–3272

    PubMed  Google Scholar 

  16. Niinimäki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Pääkkö EL, Möttönen MI, Lanning M (2008) Osteonecrosis in children treated for lymphoma or solid tumors. J Pediatr Hematol Oncol 30:798–802

    Article  PubMed  Google Scholar 

  17. Carey JJ, Palomo L (2008) Bisphosphonate and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 75:871–879

    Article  PubMed  Google Scholar 

  18. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  19. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376

    Google Scholar 

  20. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2007) American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Google Scholar 

  21. Ruggiero S, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  22. Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72:919–929

    PubMed  Google Scholar 

  23. Brown JJ, Ramalingam L, Zacharin MR (2008) Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol 68:863–867

    Article  CAS  Google Scholar 

  24. Malmgren B, Åström E, Söderhäll S (2008) No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37:196–200

    Article  PubMed  CAS  Google Scholar 

  25. Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153:719–720

    Article  PubMed  CAS  Google Scholar 

  26. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS (2007) Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 41:276–284

    Article  PubMed  CAS  Google Scholar 

  27. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365–383

    Article  PubMed  CAS  Google Scholar 

  28. Duan X, Xia Z, Zhang H, Quijano M, Dobson R, Barnett B, Triffitt J, Dunford J, Ebetino F, Russel RG (2010) Determination of the relative bone mineral-binding affinities of bisphosphonates by using hydroxyapatite-column chromatography combined with mass spectrometric analysis. Bone 46:S23

    Article  Google Scholar 

  29. Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033

    Article  PubMed  CAS  Google Scholar 

  30. American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137:1144–1150

    Google Scholar 

Download references

Conflict of interest

All authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital “Giambattista Rossi”, Piazzale Ludovico Antonio Scuro 10, 37134, Verona, Italy

    Evelina Maines, Elena Monti, Francesco Doro, Grazia Morandi, Paolo Cavarzere & Franco Antoniazzi

Authors
  1. Evelina Maines
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Monti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Doro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Grazia Morandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paolo Cavarzere
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franco Antoniazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evelina Maines.

About this article

Cite this article

Maines, E., Monti, E., Doro, F. et al. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab 30, 434–438 (2012). https://doi.org/10.1007/s00774-011-0331-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-011-0331-3

Keywords

Search

Navigation